Plasma-derived coagulation factor replacement

This entry refers to the replacement of coagulation factors and plasma proteins (such as fibrinogen, factor VIII, factor XIII, von Willebrand factor, and others) via transfusion products including plasma, fresh frozen plasma, and cryoprecipitate[1][3][5][6][7][9][10]. Such treatments are indicated for patients who have acquired or congenital deficiencies of clotting factors, leading to increased risk of bleeding. Plasma and its derivatives are mixtures of proteins (albumin, globulins, and fibrinogen) rather than single, well-defined therapeutic targets[8]. Cryoprecipitate is particularly enriched in fibrinogen, factor VIII, factor XIII, von Willebrand factor, and fibronectin[3][6][9]. These blood products act by restoring deficient components of the coagulation cascade to re-establish effective clot formation and hemostasis. Their use is associated with notable safety challenges including immunologic and infectious complications. This entry describes a class of *therapeutic product*—not a unique molecular target—and thus should be refined into specific proteins or coagulation factors (e.g., "Fibrinogen," "Factor VIII," "Von Willebrand factor") for structured molecular targeting.

Other names

Plasma protein replacementFibrinogen replacementClotting factor replacementCryoprecipitate administrationFresh frozen plasma transfusion

Replacement of deficient plasma proteins and coagulation factors (e.g., fibrinogen, factor VIII, factor XIII, von Willebrand factor) to restore normal clotting function and achieve hemostasis